Previous close | 44.55 |
Open | 44.55 |
Bid | 0.00 |
Ask | 0.00 |
Strike | 110.00 |
Expiry date | 2022-08-19 |
Day's range | 44.55 - 44.55 |
Contract range | N/A |
Volume | |
Open interest | 1 |
You know that you can count on them for leadership in their market and earnings growth. Here, I'll focus on three companies that stand out for their strong market positions: a biotech company and a medical device company that each dominate their fields, and a pharmaceutical player on the way to winning in market share. Vertex Pharmaceuticals (NASDAQ: VRTX) is the worldwide leader in cystic fibrosis (CF) treatment.
SpringWorks' (SWTX) phase III study evaluating its investigational candidate, nirogacestat, in adult patients with progressing desmoid tumors, meets primary and key secondary endpoints.
Dividend stocks can be a great place to start looking. A couple of Dividend Kings that have been doing particularly well this year are AbbVie (NYSE: ABBV) and Altria Group (NYSE: MO). AbbVie is a top healthcare stock that yields 3.7% annually, which is more than double the S&P 500 average of less than 1.4%.